torcetrapib has been researched along with Apoplexy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeLisle, RK; Ganz, P; Hyde, C; Malarstig, A; Murthy, AC; Ostroff, R; Segal, MR; Weiss, SJ; Williams, SA | 1 |
| Francis, DP; Keene, D; Price, C; Shun-Shin, MJ | 1 |
1 review(s) available for torcetrapib and Apoplexy
| Article | Year |
|---|---|
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Myocardial Infarction; Niacin; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Stroke; Sulfhydryl Compounds | 2014 |
1 trial(s) available for torcetrapib and Apoplexy
| Article | Year |
|---|---|
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Cholesterol Ester Transfer Proteins; Drug-Related Side Effects and Adverse Reactions; Early Diagnosis; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Proteomics; Quinolines; Stroke; Survival Analysis | 2018 |